Role of CD36 in central nervous system diseases  

作　　者：Min Feng Qiang Zhou Huimin Xie Chang Liu Mengru Zheng Shuyu Zhang Songlin Zhou Jian Zhao 

机构地区：[1]School of Health Science and Engineering,University of Shanghai for Science and Technology,Shanghai,China [2]Department of Orthopedic Oncology,Second Affiliated Hospital of Naval Medical University,Shanghai,China [3]Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education,NMPA Key Laboratory for Research and Evaluation of Tissue Engineering Technology Products,Jiangsu Clinical Medicine Center of Tissue Engineering and Nerve Injury Repair,Co-Innovation Center of Neuroregeneration,Nantong University,Nantong,Jiangsu Province,China [4]Department of Stomatology,Affiliated Hospital of Nantong University,Nantong,Jiangsu Province,China [5]Medical College of Nantong University,Nantong,Jiangsu Province,China

出　　处：《Neural Regeneration Research》2024年第3期512-518,共7页中国神经再生研究（英文版）

基　　金：supported by the National Major Project of Research and Development,No.2022YFA1105500(to SZ);the National Natural Science Foundation of China,No.81870975(to SZ);Innovation Program for Graduate Students in Jiangsu Province of China,No.KYCX223335(to MZ)。

摘　　要：CD36 is a highly glycosylated integral membrane protein that belongs to the scavenger receptor class B family and regulates the pathological progress of metabolic diseases.CD36 was recently found to be widely expressed in various cell types in the nervous system,including endothelial cells,pericytes,astrocytes,and microglia.CD36 mediates a number of regulatory processes,such as endothelial dysfunction,oxidative stress,mitochondrial dysfunction,and inflammatory responses,which are involved in many central nervous system diseases,such as stroke,Alzheimer’s disease,Parkinson’s disease,and spinal cord injury.CD36 antagonists can suppress CD36 expression or prevent CD36 binding to its ligand,thereby achieving inhibition of CD36-mediated pathways or functions.Here,we reviewed the mechanisms of action of CD36 antagonists,such as Salvianolic acid B,tanshinone IIA,curcumin,sulfosuccinimidyl oleate,antioxidants,and small-molecule compounds.Moreover,we predicted the structures of binding sites between CD36 and antagonists.These sites can provide targets for more efficient and safer CD36 antagonists for the treatment of central nervous system diseases.

关 键 词：animal experiments ANTAGONISTS CD36 antagonist central nervous system diseases clinical trial curcumin microRNA salvianolic acid B small-molecule drugs sulfosuccinimidyl oleate 

分 类 号：R741[医药卫生—神经病学与精神病学]